nodes	percent_of_prediction	percent_of_DWPC	metapath
Zoledronate—ABCC1—Dactinomycin—testicular cancer	0.187	0.272	CbGbCtD
Zoledronate—ABCC1—Epirubicin—testicular cancer	0.135	0.197	CbGbCtD
Zoledronate—ABCC1—Vinblastine—testicular cancer	0.117	0.171	CbGbCtD
Zoledronate—ABCC1—Etoposide—testicular cancer	0.105	0.154	CbGbCtD
Zoledronate—ABCC1—Doxorubicin—testicular cancer	0.0718	0.105	CbGbCtD
Zoledronate—ABCC1—Methotrexate—testicular cancer	0.0696	0.102	CbGbCtD
Zoledronate—GGPS1—seminal vesicle—testicular cancer	0.00878	0.147	CbGeAlD
Zoledronate—GGPS1—gonad—testicular cancer	0.00634	0.106	CbGeAlD
Zoledronate—CA14—seminal vesicle—testicular cancer	0.00525	0.0879	CbGeAlD
Zoledronate—GGPS1—female gonad—testicular cancer	0.00515	0.0864	CbGeAlD
Zoledronate—GGPS1—testis—testicular cancer	0.00457	0.0766	CbGeAlD
Zoledronate—FDPS—seminal vesicle—testicular cancer	0.00405	0.0678	CbGeAlD
Zoledronate—GGPS1—lymph node—testicular cancer	0.00331	0.0555	CbGeAlD
Zoledronate—FDPS—gonad—testicular cancer	0.00292	0.049	CbGeAlD
Zoledronate—FDPS—female gonad—testicular cancer	0.00238	0.0398	CbGeAlD
Zoledronate—ABCC1—seminal vesicle—testicular cancer	0.00235	0.0394	CbGeAlD
Zoledronate—CA2—embryo—testicular cancer	0.00224	0.0375	CbGeAlD
Zoledronate—FDPS—testis—testicular cancer	0.00211	0.0353	CbGeAlD
Zoledronate—CA2—seminal vesicle—testicular cancer	0.0021	0.0352	CbGeAlD
Zoledronate—FDPS—lymph node—testicular cancer	0.00153	0.0256	CbGeAlD
Zoledronate—ABCC1—female gonad—testicular cancer	0.00138	0.0231	CbGeAlD
Zoledronate—CA2—female gonad—testicular cancer	0.00123	0.0207	CbGeAlD
Zoledronate—ABCC1—testis—testicular cancer	0.00122	0.0205	CbGeAlD
Zoledronate—CA2—testis—testicular cancer	0.00109	0.0183	CbGeAlD
Zoledronate—ABCC1—lymph node—testicular cancer	0.000887	0.0149	CbGeAlD
Zoledronate—CA2—lymph node—testicular cancer	0.000793	0.0133	CbGeAlD
Zoledronate—Gastrointestinal pain—Etoposide—testicular cancer	0.00018	0.000704	CcSEcCtD
Zoledronate—Infestation NOS—Doxorubicin—testicular cancer	0.000179	0.0007	CcSEcCtD
Zoledronate—Infestation—Doxorubicin—testicular cancer	0.000179	0.0007	CcSEcCtD
Zoledronate—Vomiting—Ifosfamide—testicular cancer	0.000177	0.000693	CcSEcCtD
Zoledronate—Hypersensitivity—Cisplatin—testicular cancer	0.000177	0.000693	CcSEcCtD
Zoledronate—Bradycardia—Epirubicin—testicular cancer	0.000176	0.000692	CcSEcCtD
Zoledronate—Renal failure—Doxorubicin—testicular cancer	0.000176	0.000688	CcSEcCtD
Zoledronate—Rash—Ifosfamide—testicular cancer	0.000175	0.000687	CcSEcCtD
Zoledronate—Dermatitis—Ifosfamide—testicular cancer	0.000175	0.000687	CcSEcCtD
Zoledronate—Urticaria—Etoposide—testicular cancer	0.000175	0.000684	CcSEcCtD
Zoledronate—Stomatitis—Doxorubicin—testicular cancer	0.000174	0.000683	CcSEcCtD
Zoledronate—Abdominal pain—Etoposide—testicular cancer	0.000174	0.000681	CcSEcCtD
Zoledronate—Body temperature increased—Etoposide—testicular cancer	0.000174	0.000681	CcSEcCtD
Zoledronate—Urinary tract infection—Doxorubicin—testicular cancer	0.000174	0.000681	CcSEcCtD
Zoledronate—Conjunctivitis—Doxorubicin—testicular cancer	0.000174	0.000681	CcSEcCtD
Zoledronate—Eye disorder—Methotrexate—testicular cancer	0.000173	0.000678	CcSEcCtD
Zoledronate—Hypoaesthesia—Epirubicin—testicular cancer	0.000172	0.000676	CcSEcCtD
Zoledronate—Asthenia—Cisplatin—testicular cancer	0.000172	0.000674	CcSEcCtD
Zoledronate—Cardiac disorder—Methotrexate—testicular cancer	0.000172	0.000674	CcSEcCtD
Zoledronate—Urinary tract disorder—Epirubicin—testicular cancer	0.000171	0.000671	CcSEcCtD
Zoledronate—Oedema peripheral—Epirubicin—testicular cancer	0.000171	0.000669	CcSEcCtD
Zoledronate—Haematuria—Doxorubicin—testicular cancer	0.00017	0.000668	CcSEcCtD
Zoledronate—Connective tissue disorder—Epirubicin—testicular cancer	0.00017	0.000668	CcSEcCtD
Zoledronate—Urethral disorder—Epirubicin—testicular cancer	0.00017	0.000666	CcSEcCtD
Zoledronate—Angiopathy—Methotrexate—testicular cancer	0.000168	0.000659	CcSEcCtD
Zoledronate—Immune system disorder—Methotrexate—testicular cancer	0.000167	0.000656	CcSEcCtD
Zoledronate—Mediastinal disorder—Methotrexate—testicular cancer	0.000167	0.000654	CcSEcCtD
Zoledronate—Agranulocytosis—Doxorubicin—testicular cancer	0.000167	0.000653	CcSEcCtD
Zoledronate—Chills—Methotrexate—testicular cancer	0.000166	0.000651	CcSEcCtD
Zoledronate—Nausea—Ifosfamide—testicular cancer	0.000165	0.000648	CcSEcCtD
Zoledronate—Diarrhoea—Cisplatin—testicular cancer	0.000164	0.000643	CcSEcCtD
Zoledronate—Alopecia—Methotrexate—testicular cancer	0.000164	0.000642	CcSEcCtD
Zoledronate—Bradycardia—Doxorubicin—testicular cancer	0.000163	0.00064	CcSEcCtD
Zoledronate—Mental disorder—Methotrexate—testicular cancer	0.000162	0.000636	CcSEcCtD
Zoledronate—Eye disorder—Epirubicin—testicular cancer	0.000162	0.000635	CcSEcCtD
Zoledronate—Hypersensitivity—Etoposide—testicular cancer	0.000162	0.000634	CcSEcCtD
Zoledronate—Erythema—Methotrexate—testicular cancer	0.000161	0.000632	CcSEcCtD
Zoledronate—Malnutrition—Methotrexate—testicular cancer	0.000161	0.000632	CcSEcCtD
Zoledronate—Flushing—Epirubicin—testicular cancer	0.000161	0.000631	CcSEcCtD
Zoledronate—Cardiac disorder—Epirubicin—testicular cancer	0.000161	0.000631	CcSEcCtD
Zoledronate—Hypoaesthesia—Doxorubicin—testicular cancer	0.00016	0.000625	CcSEcCtD
Zoledronate—Urinary tract disorder—Doxorubicin—testicular cancer	0.000158	0.000621	CcSEcCtD
Zoledronate—Oedema peripheral—Doxorubicin—testicular cancer	0.000158	0.000619	CcSEcCtD
Zoledronate—Dysgeusia—Methotrexate—testicular cancer	0.000158	0.000619	CcSEcCtD
Zoledronate—Asthenia—Etoposide—testicular cancer	0.000158	0.000618	CcSEcCtD
Zoledronate—Connective tissue disorder—Doxorubicin—testicular cancer	0.000158	0.000618	CcSEcCtD
Zoledronate—Angiopathy—Epirubicin—testicular cancer	0.000157	0.000616	CcSEcCtD
Zoledronate—Urethral disorder—Doxorubicin—testicular cancer	0.000157	0.000616	CcSEcCtD
Zoledronate—Immune system disorder—Epirubicin—testicular cancer	0.000157	0.000614	CcSEcCtD
Zoledronate—Mediastinal disorder—Epirubicin—testicular cancer	0.000156	0.000612	CcSEcCtD
Zoledronate—Back pain—Methotrexate—testicular cancer	0.000156	0.000611	CcSEcCtD
Zoledronate—Chills—Epirubicin—testicular cancer	0.000156	0.00061	CcSEcCtD
Zoledronate—Pruritus—Etoposide—testicular cancer	0.000155	0.000609	CcSEcCtD
Zoledronate—Arrhythmia—Epirubicin—testicular cancer	0.000155	0.000607	CcSEcCtD
Zoledronate—Alopecia—Epirubicin—testicular cancer	0.000153	0.0006	CcSEcCtD
Zoledronate—Vomiting—Cisplatin—testicular cancer	0.000152	0.000598	CcSEcCtD
Zoledronate—Vision blurred—Methotrexate—testicular cancer	0.000152	0.000596	CcSEcCtD
Zoledronate—Mental disorder—Epirubicin—testicular cancer	0.000152	0.000595	CcSEcCtD
Zoledronate—Rash—Cisplatin—testicular cancer	0.000151	0.000593	CcSEcCtD
Zoledronate—Dermatitis—Cisplatin—testicular cancer	0.000151	0.000592	CcSEcCtD
Zoledronate—Malnutrition—Epirubicin—testicular cancer	0.000151	0.000591	CcSEcCtD
Zoledronate—Erythema—Epirubicin—testicular cancer	0.000151	0.000591	CcSEcCtD
Zoledronate—Diarrhoea—Etoposide—testicular cancer	0.00015	0.000589	CcSEcCtD
Zoledronate—Eye disorder—Doxorubicin—testicular cancer	0.00015	0.000587	CcSEcCtD
Zoledronate—Ill-defined disorder—Methotrexate—testicular cancer	0.00015	0.000586	CcSEcCtD
Zoledronate—Anaemia—Methotrexate—testicular cancer	0.000149	0.000584	CcSEcCtD
Zoledronate—Flushing—Doxorubicin—testicular cancer	0.000149	0.000583	CcSEcCtD
Zoledronate—Cardiac disorder—Doxorubicin—testicular cancer	0.000149	0.000583	CcSEcCtD
Zoledronate—Dysgeusia—Epirubicin—testicular cancer	0.000148	0.000579	CcSEcCtD
Zoledronate—Back pain—Epirubicin—testicular cancer	0.000146	0.000572	CcSEcCtD
Zoledronate—Angiopathy—Doxorubicin—testicular cancer	0.000146	0.00057	CcSEcCtD
Zoledronate—Malaise—Methotrexate—testicular cancer	0.000145	0.00057	CcSEcCtD
Zoledronate—Dizziness—Etoposide—testicular cancer	0.000145	0.000569	CcSEcCtD
Zoledronate—Muscle spasms—Epirubicin—testicular cancer	0.000145	0.000569	CcSEcCtD
Zoledronate—Immune system disorder—Doxorubicin—testicular cancer	0.000145	0.000568	CcSEcCtD
Zoledronate—Vertigo—Methotrexate—testicular cancer	0.000145	0.000568	CcSEcCtD
Zoledronate—Mediastinal disorder—Doxorubicin—testicular cancer	0.000145	0.000567	CcSEcCtD
Zoledronate—Leukopenia—Methotrexate—testicular cancer	0.000144	0.000566	CcSEcCtD
Zoledronate—Chills—Doxorubicin—testicular cancer	0.000144	0.000564	CcSEcCtD
Zoledronate—Arrhythmia—Doxorubicin—testicular cancer	0.000143	0.000562	CcSEcCtD
Zoledronate—Nausea—Cisplatin—testicular cancer	0.000142	0.000558	CcSEcCtD
Zoledronate—Vision blurred—Epirubicin—testicular cancer	0.000142	0.000557	CcSEcCtD
Zoledronate—Alopecia—Doxorubicin—testicular cancer	0.000142	0.000556	CcSEcCtD
Zoledronate—Cough—Methotrexate—testicular cancer	0.000141	0.000551	CcSEcCtD
Zoledronate—Mental disorder—Doxorubicin—testicular cancer	0.000141	0.000551	CcSEcCtD
Zoledronate—Ill-defined disorder—Epirubicin—testicular cancer	0.00014	0.000549	CcSEcCtD
Zoledronate—Convulsion—Methotrexate—testicular cancer	0.00014	0.000548	CcSEcCtD
Zoledronate—Vomiting—Etoposide—testicular cancer	0.00014	0.000547	CcSEcCtD
Zoledronate—Erythema—Doxorubicin—testicular cancer	0.00014	0.000547	CcSEcCtD
Zoledronate—Malnutrition—Doxorubicin—testicular cancer	0.00014	0.000547	CcSEcCtD
Zoledronate—Anaemia—Epirubicin—testicular cancer	0.000139	0.000547	CcSEcCtD
Zoledronate—Agitation—Epirubicin—testicular cancer	0.000139	0.000544	CcSEcCtD
Zoledronate—Rash—Etoposide—testicular cancer	0.000139	0.000543	CcSEcCtD
Zoledronate—Dermatitis—Etoposide—testicular cancer	0.000138	0.000542	CcSEcCtD
Zoledronate—Headache—Etoposide—testicular cancer	0.000138	0.000539	CcSEcCtD
Zoledronate—Chest pain—Methotrexate—testicular cancer	0.000137	0.000538	CcSEcCtD
Zoledronate—Arthralgia—Methotrexate—testicular cancer	0.000137	0.000538	CcSEcCtD
Zoledronate—Myalgia—Methotrexate—testicular cancer	0.000137	0.000538	CcSEcCtD
Zoledronate—Dysgeusia—Doxorubicin—testicular cancer	0.000137	0.000536	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000136	0.000534	CcSEcCtD
Zoledronate—Malaise—Epirubicin—testicular cancer	0.000136	0.000533	CcSEcCtD
Zoledronate—Discomfort—Methotrexate—testicular cancer	0.000136	0.000532	CcSEcCtD
Zoledronate—Vertigo—Epirubicin—testicular cancer	0.000136	0.000531	CcSEcCtD
Zoledronate—Syncope—Epirubicin—testicular cancer	0.000135	0.00053	CcSEcCtD
Zoledronate—Leukopenia—Epirubicin—testicular cancer	0.000135	0.000529	CcSEcCtD
Zoledronate—Back pain—Doxorubicin—testicular cancer	0.000135	0.000529	CcSEcCtD
Zoledronate—Muscle spasms—Doxorubicin—testicular cancer	0.000134	0.000526	CcSEcCtD
Zoledronate—Palpitations—Epirubicin—testicular cancer	0.000133	0.000523	CcSEcCtD
Zoledronate—Confusional state—Methotrexate—testicular cancer	0.000133	0.00052	CcSEcCtD
Zoledronate—Loss of consciousness—Epirubicin—testicular cancer	0.000133	0.00052	CcSEcCtD
Zoledronate—Cough—Epirubicin—testicular cancer	0.000132	0.000516	CcSEcCtD
Zoledronate—Anaphylactic shock—Methotrexate—testicular cancer	0.000132	0.000516	CcSEcCtD
Zoledronate—Vision blurred—Doxorubicin—testicular cancer	0.000132	0.000516	CcSEcCtD
Zoledronate—Convulsion—Epirubicin—testicular cancer	0.000131	0.000512	CcSEcCtD
Zoledronate—Infection—Methotrexate—testicular cancer	0.000131	0.000512	CcSEcCtD
Zoledronate—Nausea—Etoposide—testicular cancer	0.00013	0.000511	CcSEcCtD
Zoledronate—Hypertension—Epirubicin—testicular cancer	0.00013	0.000511	CcSEcCtD
Zoledronate—Ill-defined disorder—Doxorubicin—testicular cancer	0.00013	0.000508	CcSEcCtD
Zoledronate—Nervous system disorder—Methotrexate—testicular cancer	0.000129	0.000506	CcSEcCtD
Zoledronate—Anaemia—Doxorubicin—testicular cancer	0.000129	0.000506	CcSEcCtD
Zoledronate—Thrombocytopenia—Methotrexate—testicular cancer	0.000129	0.000505	CcSEcCtD
Zoledronate—Chest pain—Epirubicin—testicular cancer	0.000128	0.000504	CcSEcCtD
Zoledronate—Myalgia—Epirubicin—testicular cancer	0.000128	0.000504	CcSEcCtD
Zoledronate—Arthralgia—Epirubicin—testicular cancer	0.000128	0.000504	CcSEcCtD
Zoledronate—Agitation—Doxorubicin—testicular cancer	0.000128	0.000503	CcSEcCtD
Zoledronate—Anxiety—Epirubicin—testicular cancer	0.000128	0.000502	CcSEcCtD
Zoledronate—Skin disorder—Methotrexate—testicular cancer	0.000128	0.000501	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000128	0.0005	CcSEcCtD
Zoledronate—Hyperhidrosis—Methotrexate—testicular cancer	0.000127	0.000499	CcSEcCtD
Zoledronate—Discomfort—Epirubicin—testicular cancer	0.000127	0.000497	CcSEcCtD
Zoledronate—Malaise—Doxorubicin—testicular cancer	0.000126	0.000493	CcSEcCtD
Zoledronate—Dry mouth—Epirubicin—testicular cancer	0.000126	0.000492	CcSEcCtD
Zoledronate—Vertigo—Doxorubicin—testicular cancer	0.000125	0.000492	CcSEcCtD
Zoledronate—Anorexia—Methotrexate—testicular cancer	0.000125	0.000492	CcSEcCtD
Zoledronate—Syncope—Doxorubicin—testicular cancer	0.000125	0.000491	CcSEcCtD
Zoledronate—Leukopenia—Doxorubicin—testicular cancer	0.000125	0.00049	CcSEcCtD
Zoledronate—Confusional state—Epirubicin—testicular cancer	0.000124	0.000487	CcSEcCtD
Zoledronate—Palpitations—Doxorubicin—testicular cancer	0.000123	0.000484	CcSEcCtD
Zoledronate—Oedema—Epirubicin—testicular cancer	0.000123	0.000483	CcSEcCtD
Zoledronate—Anaphylactic shock—Epirubicin—testicular cancer	0.000123	0.000483	CcSEcCtD
Zoledronate—Hypotension—Methotrexate—testicular cancer	0.000123	0.000482	CcSEcCtD
Zoledronate—Loss of consciousness—Doxorubicin—testicular cancer	0.000123	0.000481	CcSEcCtD
Zoledronate—Infection—Epirubicin—testicular cancer	0.000122	0.00048	CcSEcCtD
Zoledronate—Cough—Doxorubicin—testicular cancer	0.000122	0.000478	CcSEcCtD
Zoledronate—Shock—Epirubicin—testicular cancer	0.000121	0.000475	CcSEcCtD
Zoledronate—Convulsion—Doxorubicin—testicular cancer	0.000121	0.000474	CcSEcCtD
Zoledronate—Nervous system disorder—Epirubicin—testicular cancer	0.000121	0.000473	CcSEcCtD
Zoledronate—Thrombocytopenia—Epirubicin—testicular cancer	0.000121	0.000473	CcSEcCtD
Zoledronate—Hypertension—Doxorubicin—testicular cancer	0.000121	0.000472	CcSEcCtD
Zoledronate—Tachycardia—Epirubicin—testicular cancer	0.00012	0.000471	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00012	0.00047	CcSEcCtD
Zoledronate—Skin disorder—Epirubicin—testicular cancer	0.00012	0.000469	CcSEcCtD
Zoledronate—Hyperhidrosis—Epirubicin—testicular cancer	0.000119	0.000467	CcSEcCtD
Zoledronate—Insomnia—Methotrexate—testicular cancer	0.000119	0.000467	CcSEcCtD
Zoledronate—Chest pain—Doxorubicin—testicular cancer	0.000119	0.000466	CcSEcCtD
Zoledronate—Myalgia—Doxorubicin—testicular cancer	0.000119	0.000466	CcSEcCtD
Zoledronate—Arthralgia—Doxorubicin—testicular cancer	0.000119	0.000466	CcSEcCtD
Zoledronate—Anxiety—Doxorubicin—testicular cancer	0.000118	0.000464	CcSEcCtD
Zoledronate—Paraesthesia—Methotrexate—testicular cancer	0.000118	0.000463	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000118	0.000463	CcSEcCtD
Zoledronate—Discomfort—Doxorubicin—testicular cancer	0.000117	0.00046	CcSEcCtD
Zoledronate—Anorexia—Epirubicin—testicular cancer	0.000117	0.00046	CcSEcCtD
Zoledronate—Dyspnoea—Methotrexate—testicular cancer	0.000117	0.00046	CcSEcCtD
Zoledronate—Somnolence—Methotrexate—testicular cancer	0.000117	0.000459	CcSEcCtD
Zoledronate—Dry mouth—Doxorubicin—testicular cancer	0.000116	0.000456	CcSEcCtD
Zoledronate—Dyspepsia—Methotrexate—testicular cancer	0.000116	0.000454	CcSEcCtD
Zoledronate—Hypotension—Epirubicin—testicular cancer	0.000115	0.000451	CcSEcCtD
Zoledronate—Confusional state—Doxorubicin—testicular cancer	0.000115	0.00045	CcSEcCtD
Zoledronate—Decreased appetite—Methotrexate—testicular cancer	0.000114	0.000448	CcSEcCtD
Zoledronate—Oedema—Doxorubicin—testicular cancer	0.000114	0.000447	CcSEcCtD
Zoledronate—Anaphylactic shock—Doxorubicin—testicular cancer	0.000114	0.000447	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000114	0.000445	CcSEcCtD
Zoledronate—Fatigue—Methotrexate—testicular cancer	0.000113	0.000445	CcSEcCtD
Zoledronate—Infection—Doxorubicin—testicular cancer	0.000113	0.000444	CcSEcCtD
Zoledronate—Pain—Methotrexate—testicular cancer	0.000113	0.000441	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000112	0.00044	CcSEcCtD
Zoledronate—Shock—Doxorubicin—testicular cancer	0.000112	0.000439	CcSEcCtD
Zoledronate—Nervous system disorder—Doxorubicin—testicular cancer	0.000112	0.000438	CcSEcCtD
Zoledronate—Thrombocytopenia—Doxorubicin—testicular cancer	0.000112	0.000437	CcSEcCtD
Zoledronate—Insomnia—Epirubicin—testicular cancer	0.000111	0.000437	CcSEcCtD
Zoledronate—Tachycardia—Doxorubicin—testicular cancer	0.000111	0.000436	CcSEcCtD
Zoledronate—Skin disorder—Doxorubicin—testicular cancer	0.000111	0.000434	CcSEcCtD
Zoledronate—Paraesthesia—Epirubicin—testicular cancer	0.000111	0.000433	CcSEcCtD
Zoledronate—Hyperhidrosis—Doxorubicin—testicular cancer	0.00011	0.000432	CcSEcCtD
Zoledronate—Dyspnoea—Epirubicin—testicular cancer	0.00011	0.00043	CcSEcCtD
Zoledronate—Somnolence—Epirubicin—testicular cancer	0.000109	0.000429	CcSEcCtD
Zoledronate—Anorexia—Doxorubicin—testicular cancer	0.000109	0.000426	CcSEcCtD
Zoledronate—Feeling abnormal—Methotrexate—testicular cancer	0.000108	0.000425	CcSEcCtD
Zoledronate—Dyspepsia—Epirubicin—testicular cancer	0.000108	0.000425	CcSEcCtD
Zoledronate—Gastrointestinal pain—Methotrexate—testicular cancer	0.000108	0.000422	CcSEcCtD
Zoledronate—Decreased appetite—Epirubicin—testicular cancer	0.000107	0.00042	CcSEcCtD
Zoledronate—Hypotension—Doxorubicin—testicular cancer	0.000106	0.000417	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000106	0.000417	CcSEcCtD
Zoledronate—Fatigue—Epirubicin—testicular cancer	0.000106	0.000416	CcSEcCtD
Zoledronate—Pain—Epirubicin—testicular cancer	0.000105	0.000413	CcSEcCtD
Zoledronate—Constipation—Epirubicin—testicular cancer	0.000105	0.000413	CcSEcCtD
Zoledronate—Urticaria—Methotrexate—testicular cancer	0.000105	0.00041	CcSEcCtD
Zoledronate—Body temperature increased—Methotrexate—testicular cancer	0.000104	0.000408	CcSEcCtD
Zoledronate—Abdominal pain—Methotrexate—testicular cancer	0.000104	0.000408	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000104	0.000407	CcSEcCtD
Zoledronate—Insomnia—Doxorubicin—testicular cancer	0.000103	0.000404	CcSEcCtD
Zoledronate—Paraesthesia—Doxorubicin—testicular cancer	0.000102	0.000401	CcSEcCtD
Zoledronate—Dyspnoea—Doxorubicin—testicular cancer	0.000102	0.000398	CcSEcCtD
Zoledronate—Feeling abnormal—Epirubicin—testicular cancer	0.000101	0.000398	CcSEcCtD
Zoledronate—Somnolence—Doxorubicin—testicular cancer	0.000101	0.000397	CcSEcCtD
Zoledronate—Gastrointestinal pain—Epirubicin—testicular cancer	0.000101	0.000395	CcSEcCtD
Zoledronate—Dyspepsia—Doxorubicin—testicular cancer	0.0001	0.000393	CcSEcCtD
Zoledronate—Decreased appetite—Doxorubicin—testicular cancer	9.9e-05	0.000388	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Doxorubicin—testicular cancer	9.84e-05	0.000386	CcSEcCtD
Zoledronate—Fatigue—Doxorubicin—testicular cancer	9.82e-05	0.000385	CcSEcCtD
Zoledronate—Urticaria—Epirubicin—testicular cancer	9.78e-05	0.000383	CcSEcCtD
Zoledronate—Pain—Doxorubicin—testicular cancer	9.74e-05	0.000382	CcSEcCtD
Zoledronate—Constipation—Doxorubicin—testicular cancer	9.74e-05	0.000382	CcSEcCtD
Zoledronate—Abdominal pain—Epirubicin—testicular cancer	9.73e-05	0.000382	CcSEcCtD
Zoledronate—Body temperature increased—Epirubicin—testicular cancer	9.73e-05	0.000382	CcSEcCtD
Zoledronate—Hypersensitivity—Methotrexate—testicular cancer	9.69e-05	0.00038	CcSEcCtD
Zoledronate—Asthenia—Methotrexate—testicular cancer	9.44e-05	0.00037	CcSEcCtD
Zoledronate—Feeling abnormal—Doxorubicin—testicular cancer	9.39e-05	0.000368	CcSEcCtD
Zoledronate—Gastrointestinal pain—Doxorubicin—testicular cancer	9.32e-05	0.000365	CcSEcCtD
Zoledronate—Pruritus—Methotrexate—testicular cancer	9.31e-05	0.000365	CcSEcCtD
Zoledronate—Hypersensitivity—Epirubicin—testicular cancer	9.07e-05	0.000356	CcSEcCtD
Zoledronate—Urticaria—Doxorubicin—testicular cancer	9.05e-05	0.000355	CcSEcCtD
Zoledronate—Body temperature increased—Doxorubicin—testicular cancer	9.01e-05	0.000353	CcSEcCtD
Zoledronate—Abdominal pain—Doxorubicin—testicular cancer	9.01e-05	0.000353	CcSEcCtD
Zoledronate—Diarrhoea—Methotrexate—testicular cancer	9e-05	0.000353	CcSEcCtD
Zoledronate—Asthenia—Epirubicin—testicular cancer	8.83e-05	0.000346	CcSEcCtD
Zoledronate—Pruritus—Epirubicin—testicular cancer	8.71e-05	0.000342	CcSEcCtD
Zoledronate—Dizziness—Methotrexate—testicular cancer	8.7e-05	0.000341	CcSEcCtD
Zoledronate—Diarrhoea—Epirubicin—testicular cancer	8.43e-05	0.00033	CcSEcCtD
Zoledronate—Hypersensitivity—Doxorubicin—testicular cancer	8.39e-05	0.000329	CcSEcCtD
Zoledronate—Vomiting—Methotrexate—testicular cancer	8.37e-05	0.000328	CcSEcCtD
Zoledronate—Rash—Methotrexate—testicular cancer	8.3e-05	0.000325	CcSEcCtD
Zoledronate—Dermatitis—Methotrexate—testicular cancer	8.29e-05	0.000325	CcSEcCtD
Zoledronate—Headache—Methotrexate—testicular cancer	8.24e-05	0.000323	CcSEcCtD
Zoledronate—Asthenia—Doxorubicin—testicular cancer	8.17e-05	0.00032	CcSEcCtD
Zoledronate—Dizziness—Epirubicin—testicular cancer	8.14e-05	0.000319	CcSEcCtD
Zoledronate—Pruritus—Doxorubicin—testicular cancer	8.06e-05	0.000316	CcSEcCtD
Zoledronate—Vomiting—Epirubicin—testicular cancer	7.83e-05	0.000307	CcSEcCtD
Zoledronate—Nausea—Methotrexate—testicular cancer	7.82e-05	0.000306	CcSEcCtD
Zoledronate—Diarrhoea—Doxorubicin—testicular cancer	7.8e-05	0.000306	CcSEcCtD
Zoledronate—Rash—Epirubicin—testicular cancer	7.76e-05	0.000304	CcSEcCtD
Zoledronate—Dermatitis—Epirubicin—testicular cancer	7.76e-05	0.000304	CcSEcCtD
Zoledronate—Headache—Epirubicin—testicular cancer	7.71e-05	0.000302	CcSEcCtD
Zoledronate—Dizziness—Doxorubicin—testicular cancer	7.53e-05	0.000295	CcSEcCtD
Zoledronate—Nausea—Epirubicin—testicular cancer	7.31e-05	0.000287	CcSEcCtD
Zoledronate—Vomiting—Doxorubicin—testicular cancer	7.24e-05	0.000284	CcSEcCtD
Zoledronate—Rash—Doxorubicin—testicular cancer	7.18e-05	0.000282	CcSEcCtD
Zoledronate—Dermatitis—Doxorubicin—testicular cancer	7.18e-05	0.000281	CcSEcCtD
Zoledronate—Headache—Doxorubicin—testicular cancer	7.14e-05	0.00028	CcSEcCtD
Zoledronate—Nausea—Doxorubicin—testicular cancer	6.77e-05	0.000265	CcSEcCtD
